

The following list contains medications which will be reviewed using the Oncology Drugs Criteria listed at: [PA criteria sheets/Minnesota Department of Human Services](#)

| <b>Minnesota Health Care Programs FFS<br/>Oncology Drug List<br/>Effective: July 1, 2025</b> |                               |
|----------------------------------------------------------------------------------------------|-------------------------------|
| <b>Drug Name</b>                                                                             | <b>Strength and Dose Form</b> |
| <b>ABIRATERONE</b>                                                                           | 250 MG TABLET                 |
|                                                                                              | 500 MG TABLET                 |
| <b>ADCETRIS</b>                                                                              | 50 MG VIAL                    |
| <b>ADSTILADRIN</b>                                                                           | 3x10 <sup>11</sup> VP/ML VIAL |
| <b>AKEEGA</b>                                                                                | 50–500 MG TABLET              |
|                                                                                              | 100–500 MG TABLET             |
| <b>ALECENSA</b>                                                                              | 150 MG CAPSULE                |
| <b>ALIQOPA</b>                                                                               | 60 MG VIAL                    |
| <b>ALUNBRIG</b>                                                                              | 30 MG TABLET                  |
|                                                                                              | 90 MG TABLET                  |
|                                                                                              | 180 MG TABLET                 |
|                                                                                              | 90 MG–180 MG TABLET PACK      |
| <b>AUGTYRO</b>                                                                               | 40 MG CAPSULE                 |
|                                                                                              | 160 MG CAPSULE                |
| <b>AVMAPKI–FAKZYNJA</b>                                                                      | 0.8 MG–200 MG CO-PACK         |
| <b>BALVERSA</b>                                                                              | 3 MG TABLET                   |
|                                                                                              | 4 MG TABLET                   |
|                                                                                              | 5 MG TABLET                   |
| <b>BAVENCIO</b>                                                                              | 200 MG/10 ML VIAL             |
| <b>BESPONSA</b>                                                                              | 0.9 MG VIAL                   |
| <b>BRAFTOVI</b>                                                                              | 75 MG CAPSULE                 |
| <b>BRUKINSA</b>                                                                              | 80 MG CAPSULE                 |
|                                                                                              | 100 MG CAPSULE                |
| <b>CABOMETYX</b>                                                                             | 20 MG TABLET                  |
|                                                                                              | 40 MG TABLET                  |
|                                                                                              | 60 MG TABLET                  |
| <b>CALQUENCE</b>                                                                             | 100 MG CAPSULE                |

**Minnesota Health Care Programs FFS  
Oncology Drug List  
Effective: July 1, 2025**

| <b>Drug Name</b> | <b>Strength and Dose Form</b> |
|------------------|-------------------------------|
|                  | 100 MG TABLET                 |
| <b>CAPRESLA</b>  | 100 MG TABLET                 |
|                  | 300 MG TABLET                 |
| <b>COMETRIQ</b>  | 60 MG DAILY DOSE PACK         |
|                  | 100 MG DAILY DOSE PACK        |
|                  | 140 MG DAILY DOSE PACK        |
| <b>COPIKTRA</b>  | 15 MG CAPSULE                 |
|                  | 25 MG CAPSULE                 |
| <b>COTELLIC</b>  | 20 MG TABLET                  |
| <b>DANZITEN</b>  | 71 MG TABLET                  |
|                  | 95 MG TABLET                  |
|                  | 240 MG TABLET                 |
| <b>DARZALEX</b>  | 100 MG/5 ML VIAL              |
|                  | 400 MG/20 ML VIAL             |
| <b>DATROWAY</b>  | 100 MG VIAL                   |
| <b>DAURISMO</b>  | 25 MG TABLET                  |
|                  | 100 MG TABLET                 |
| <b>ELAHERE</b>   | 100 MG/20 ML VIAL             |
| <b>ELREXFIO</b>  | 44 MG/1.1 ML VIAL             |
|                  | 76 MG/1.9 ML VIAL             |
| <b>ELZONRIS</b>  | 1000 MCG/ML VIAL              |
| <b>EMPLICITI</b> | 300 MG VIAL                   |
|                  | 400 MG VIAL                   |
| <b>EMRELIS</b>   | 20 MG VIAL                    |
|                  | 100 MG VIAL                   |
| <b>ENHERTU</b>   | 100 MG VIAL                   |
| <b>ENSACOVE</b>  | 25 MG CAPSULE                 |
|                  | 100 MG CAPSULE                |
| <b>ERIVEDGE</b>  | 150 MG CAPSULE                |
| <b>ERLEADA</b>   | 60 MG TABLET                  |

**Minnesota Health Care Programs FFS**  
**Oncology Drug List**  
**Effective: July 1, 2025**

| <b>Drug Name</b> | <b>Strength and Dose Form</b> |
|------------------|-------------------------------|
|                  | 240 MG TABLET                 |
| <b>ERWINAZE</b>  | 10,000 UNIT VIAL              |
| <b>EXKIVITY</b>  | 40 MG CAPSULE                 |
| <b>FARYDAK</b>   | 10 MG CAPSULE                 |
|                  | 15 MG CAPSULE                 |
|                  | 20 MG CAPSULE                 |
| <b>FRUZAQLA</b>  | 5 MG CAPSULE                  |
|                  | 1 MG CAPSULE                  |
| <b>GILOTRIF</b>  | 20 MG TABLET                  |
|                  | 30 MG TABLET                  |
|                  | 40 MG TABLET                  |
| <b>GOMEKLI</b>   | 1 MG CAPSULE                  |
|                  | 2 MG CAPSULE                  |
|                  | 1 MG TABLET FOR SUSP          |
| <b>GRAFAPEX</b>  | 1 GRAM VIAL                   |
|                  | 5 GRAM VIAL                   |
| <b>IBRANCE</b>   | 75 MG CAPSULE                 |
|                  | 100 MG CAPSULE                |
|                  | 125 MG CAPSULE                |
|                  | 75 MG TABLET                  |
|                  | 100 MG TABLET                 |
|                  | 125 MG TABLET                 |
| <b>IDHIFA</b>    | 50 MG TABLET                  |
|                  | 100 MG TABLET                 |
| <b>IMBRUVICA</b> | 70 MG/ML SUSP                 |
|                  | 140 MG TABLET                 |
|                  | 280 MG TABLET                 |
|                  | 420 MG TABLET                 |
|                  | 560 MG TABLET                 |
|                  | 70 MG CAPSULE                 |

**Minnesota Health Care Programs FFS  
Oncology Drug List  
Effective: July 1, 2025**

| <b>Drug Name</b> | <b>Strength and Dose Form</b> |
|------------------|-------------------------------|
|                  | 140 MG CAPSULE                |
| <b>IMDELLTRA</b> | 10 MG VIAL                    |
| <b>IMJUDO</b>    | 25 MG/1.25 ML VIAL            |
|                  | 300 MG/15 ML VIAL             |
| <b>IMLYGIC</b>   | 1 MILLION PFU/ML VIAL         |
|                  | 100 MILLION PFU/ML VIAL       |
| <b>INLYTA</b>    | 1 MG TABLET                   |
|                  | 5 MG TABLET                   |
| <b>INREBIC</b>   | 100 MG CAPSULE                |
| <b>IRESSA</b>    | 250 MG TABLET                 |
| <b>ITOVEBI</b>   | 3 MG TABLET                   |
|                  | 9 MG TABLET                   |
| <b>IWILFIN</b>   | 192 MG TABLET                 |
|                  | 345 MG TABLET                 |
| <b>JAYPIRCA</b>  | 50 MG TABLET                  |
| <b>KEYTRUDA</b>  | 100 MG/4ML VIAL               |
| <b>KIMMTRAK</b>  | 100 MCG.0.5 ML VIAL           |
| <b>KISQALI</b>   | 200 MG TABLET                 |
|                  | 400 MG TABLET                 |
|                  | 600 MG TABLET                 |
| <b>KOSELUGO</b>  | 10 MG CAPSULE                 |
|                  | 25 MG CAPSULE                 |
|                  | 100 MG TABLET                 |
| <b>KRAZATI</b>   | 200 MG TABLET                 |
| <b>LAZCLUZE</b>  | 80 MG TABLET                  |
| <b>LENVIMA</b>   | 4 MG CAPSULE                  |
|                  | 8 MG CAPSULE                  |
|                  | 10 MG CAPSULE                 |
|                  | 12 MG CAPSULE                 |
|                  | 14 MG CAPSULE                 |

**Minnesota Health Care Programs FFS  
Oncology Drug List  
Effective: July 1, 2025**

| <b>Drug Name</b>  | <b>Strength and Dose Form</b> |
|-------------------|-------------------------------|
|                   | 18 MG CAPSULE                 |
|                   | 20 MG CAPSULE                 |
|                   | 24 MG CAPSULE                 |
| <b>LIBTAYO</b>    | 350 MG/7 ML VIAL              |
| <b>LONSURF</b>    | 15 MG–6.14 MG TABLET          |
|                   | 20 MG–8.19 MG TABLET          |
| <b>LOQTORZI</b>   | 240 MG/6 ML VIAL              |
| <b>LORBRENA</b>   | 25 MG TABLET                  |
|                   | 100 MG TABLET                 |
| <b>LUMAKRAS</b>   | 120 MG TABLET                 |
|                   | 100 MG TABLET                 |
|                   | 150 MG TABLET                 |
|                   | 240 MG TABLET                 |
|                   | 320 MG TABLET                 |
| <b>LUNSUMIO</b>   | 1 MG/ML VIAL                  |
|                   | 30 MG/30 ML VIAL              |
| <b>LYNPARZA</b>   | 100 MG TABLET                 |
|                   | 150 MG TABLET                 |
| <b>LYTGOBI</b>    | 12 MG TABLET                  |
|                   | 16 MG TABLET                  |
|                   | 20 MG TABLET                  |
|                   | 160 MG TABLET                 |
| <b>MEKINIST</b>   | 0.5 MG TABLET                 |
|                   | 2 MG TABLET                   |
|                   | 0.05 MG/ML SOLUTION           |
| <b>MEKTOVI</b>    | 15 MG TABLET                  |
| <b>NERLYNX</b>    | 40 MG TABLET                  |
| <b>NILANDRON</b>  | 150 MG TABLET                 |
| <b>NILUTAMIDE</b> | 150 MG TABLET                 |
| <b>NINLARO</b>    | 2.3 MG CAPSULE                |

**Minnesota Health Care Programs FFS  
Oncology Drug List  
Effective: July 1, 2025**

| <b>Drug Name</b> | <b>Strength and Dose Form</b> |
|------------------|-------------------------------|
|                  | 3 MG CAPSULE                  |
|                  | 4 MG CAPSULE                  |
| <b>NUBEQA</b>    | 300 MG TABLET                 |
| <b>ODOMZO</b>    | 200 MG CAPSULE                |
| <b>OGSIVEO</b>   | 50 MG TABLET                  |
|                  | 160 MG TABLET                 |
| <b>OJEMDA</b>    | 25 MG/ML ORAL SUSPENSION      |
| <b>OJJAARA</b>   | 100 MG TABLET                 |
|                  | 150 MG TABLET                 |
| <b>OPDIVO</b>    | 40 MG/4 ML VIAL               |
|                  | 100 MG/10 ML VIAL             |
|                  | 120 MG/12 ML VIAL             |
|                  | 240 MG/24 ML VIAL             |
| <b>OPDUALAG</b>  | 2400–80 MG/20 ML VIAL         |
| <b>ORGOVYX</b>   | 17.7 MG TABLET                |
|                  | 120 MG TABLET                 |
| <b>ORSERDU</b>   | 86 MG TABLET                  |
| <b>PADCEV</b>    | 20 MG VIAL                    |
|                  | 30 MG VIAL                    |
| <b>PEMAZYRE</b>  | 4.5 MG TABLET                 |
|                  | 9 MG TABLET                   |
|                  | 13.5 MG TABLET                |
| <b>PIQRAY</b>    | 200 MG TABLET DAILY DOSE PACK |
|                  | 250 MG TABLET DAILY DOSE PACK |
|                  | 300 MG TABLET DAILY DOSE PACK |
| <b>POLIVY</b>    | 30 MG VIAL                    |
|                  | 140 MG VIAL                   |
| <b>POMALYST</b>  | 1 MG CAPSULE                  |
|                  | 2 MG CAPSULE                  |
|                  | 3 MG CAPSULE                  |

**Minnesota Health Care Programs FFS**  
**Oncology Drug List**  
**Effective: July 1, 2025**

| <b>Drug Name</b> | <b>Strength and Dose Form</b> |
|------------------|-------------------------------|
|                  | 4 MG CAPSULE                  |
| <b>RETEVMO</b>   | 40 MG TABLET                  |
|                  | 80 MG TABLET                  |
|                  | 120 MG TABLET                 |
|                  | 160 MG TABLET                 |
|                  | 40 MG CAPSULE                 |
|                  | 80 MG CAPSULE                 |
| <b>REVUFORJ</b>  | 25 MG TABLET                  |
|                  | 110 MG TABLET                 |
|                  | 160 MG TABLET                 |
| <b>REZLIDHIA</b> | 150 MG CAPSULE                |
| <b>ROMVIMZA</b>  | 14 MG CAPSULE                 |
|                  | 20 MG CAPSULE                 |
|                  | 30 MG CAPSULE                 |
| <b>ROZLYTREK</b> | 50 MG PELLETT PACKET          |
|                  | 100 MG CAPSULE                |
|                  | 200 MG CAPSULE                |
| <b>RUBRACA</b>   | 200 MG TABLET                 |
|                  | 250 MG TABLET                 |
|                  | 300 MG TABLET                 |
| <b>RYDAPT</b>    | 25 MG CAPSULE                 |
| <b>RYTELO</b>    | 47 MG VIAL                    |
|                  | 188 MG VIAL                   |
| <b>SARCLISA</b>  | 100 MG/5 ML VIAL              |
|                  | 500 MG/25 ML VIAL             |
| <b>STIVARGA</b>  | 40 MG TABLET                  |
| <b>TABRECTA</b>  | 150 MG TABLET                 |
|                  | 200 MG TABLET                 |
| <b>TAGRISSO</b>  | 40 MG TABLET                  |
|                  | 80 MG TABLET                  |

**Minnesota Health Care Programs FFS  
Oncology Drug List  
Effective: July 1, 2025**

| <b>Drug Name</b> | <b>Strength and Dose Form</b>  |
|------------------|--------------------------------|
| <b>TALZENNA</b>  | 0.1 MG SOFTGEL CAPSULE         |
|                  | 0.25 MG SOFTGEL CAPSULE        |
|                  | 0.35 MG SOFTGEL CAPSULE        |
|                  | 0.5 MG SOFTGEL CAPSULE         |
|                  | 0.75 MG SOFTGEL CAPSULE        |
|                  | 1 MG SOFTGEL CAPSULE           |
|                  | 0.1 MG CAPSULE                 |
|                  | 0.25 MG CAPSULE                |
|                  | 0.35 MG CAPSULE                |
|                  | 0.5 MG CAPSULE                 |
|                  | 0.75 MG CAPSULE                |
|                  | 1 MG CAPSULE                   |
| <b>TAZVERIK</b>  | 200 MG TABLET                  |
| <b>TECENTRIQ</b> | 1,200 MG/20 ML VIAL            |
|                  | 840 MG/14 ML VIAL              |
| <b>TEPMETKO</b>  | 225 MG TABLET                  |
| <b>TIBSOVO</b>   | 250 MG TABLET                  |
| <b>TIVDAK</b>    | 40 MG VIAL                     |
| <b>TRODELVY</b>  | 80 MG VIAL                     |
| <b>TRUSELTIQ</b> | 50 MG CAPSULE DAILY DOSE PACK  |
|                  | 75 MG CAPSULE DAILY DOSE PACK  |
|                  | 100 MG CAPSULE DAILY DOSE PACK |
|                  | 125 MG CAPSULE DAILY DOSE PACK |
| <b>TRUQAP</b>    | 200 MG TABLET                  |
| <b>TUKYSA</b>    | 50 MG TABLET                   |
|                  | 150 MG TABLET                  |
| <b>TURALIO</b>   | 125 MG CAPSULE                 |
|                  | 200 MG TABLET                  |
| <b>VANFLYTA</b>  | 26.5 MG TABLET                 |
| <b>VENCLEXTA</b> | STARTING PACK                  |



**Minnesota Health Care Programs FFS**  
**Oncology Drug List**  
**Effective: July 1, 2025**

| <b>Drug Name</b> | <b>Strength and Dose Form</b> |
|------------------|-------------------------------|
|                  | 10 MG TABLET                  |
|                  | 50 MG TABLET                  |
|                  | 100 MG TABLET                 |
| <b>VERZENIO</b>  | 50 MG TABLET                  |
|                  | 100 MG TABLET                 |
|                  | 150 MG TABLET                 |
|                  | 200 MG TABLET                 |
| <b>VITRAKVI</b>  | 25 MG CAPSULE                 |
|                  | 100 MG CAPSULE                |
|                  | 20 MG/ML SOLUTION             |
| <b>VONJO</b>     | 100 MG CAPSULE                |
| <b>VORANIGO</b>  | 10 MG TABLET                  |
| <b>VYLOY</b>     | 100 MG VIAL                   |
|                  | 300 MG VIAL                   |
| <b>WELIREG</b>   | 40 MG TABLET                  |
| <b>XALKORI</b>   | 20 MG PELLET                  |
|                  | 50 MG PELLET                  |
|                  | 150 MG PELLET                 |
|                  | 200 MG CAPSULE                |
|                  | 250 MG CAPSULE                |
| <b>XOSPATA</b>   | 40 MG TABLET                  |
| <b>XPOVIO</b>    | 40 MG ONCE WEEKLY DOSE        |
|                  | 60 MG ONCE WEEKLY DOSE        |
|                  | 80 MG ONCE WEEKLY DOSE        |
|                  | 100 MG ONCE WEEKLY DOSE       |
|                  | 40 MG TWICE WEEKLY DOSE       |
|                  | 60 MG TWICE WEEKLY DOSE       |
|                  | 80 MG TWICE WEEKLY DOSE       |
| <b>XTANDI</b>    | 40 MG CAPSULE                 |
|                  | 40 MG TABLET                  |

**Minnesota Health Care Programs FFS  
Oncology Drug List  
Effective: July 1, 2025**

| <b>Drug Name</b> | <b>Strength and Dose Form</b> |
|------------------|-------------------------------|
|                  | 80 MG TABLET                  |
| <b>YERVOY</b>    | 50 MG/10 ML VIAL              |
|                  | 200 MG/40 ML VIAL             |
| <b>YONDELIS</b>  | 1 MG VIAL                     |
| <b>ZEJULA</b>    | 100 MG TABLET                 |
|                  | 200 MG TABLET                 |
|                  | 300 MG TABLET                 |
|                  | 100 MG CAPSULE                |
| <b>ZELBORAF</b>  | 240 MG TABLET                 |
| <b>ZEPZELCA</b>  | 4 MG VIAL                     |
| <b>ZIIHERA</b>   | 300 MG VIAL                   |
| <b>ZYDELIG</b>   | 100 MG TABLET                 |
|                  | 150 MG TABLET                 |
| <b>ZYKADIA</b>   | 150 MG CAPSULE                |
|                  | 150 MG TABLET                 |
| <b>ZYNYZ</b>     | 500 MG/20 ML VIAL             |